Title: Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals
Authors: Chimukangara B, Giandhari J, Lessells J, Yende-Zuma N, Sartorius B, Samuel R, Khanyile KS, Stray-Pedersen B, Moodley P, Metzner KJ, Padayatchi N, Naidoo K, de Oliveira T.
Journal: Journal of Antimicrobial Chemotherapy,75, 11:3319–3326, https://doi.org/10.1093/jac/dkaa343 (2020)

Abstract

Objectives

To determine the impact of pretreatment low-abundance HIV-1 drug-resistant variants (LA-DRVs) on virological failure (VF) among HIV-1/TB-co-infected individuals treated with NNRTI first-line ART.

Methods

We conducted a case–control study of 170 adults with HIV-1/TB co-infection. Cases had at least one viral load (VL) ?1000 RNA copies/mL after ?6?months on NNRTI-based ART, and controls had sustained VLs <1000 copies/mL. We sequenced plasma viruses by Sanger and MiSeq next-generation sequencing (NGS). We assessed drug resistance mutations (DRMs) using the Stanford drug resistance database, and analysed NGS data for DRMs at ?20%, 10%, 5% and 2% thresholds. We assessed the effect of pretreatment drug resistance (PDR) on VF.

Resultsv We analysed sequences from 45 cases and 125 controls. Overall prevalence of PDR detected at a ?20% threshold was 4.7% (8/170) and was higher in cases than in controls (8.9% versus 3.2%), P?=?0.210. Participants with PDR at ?20% had almost 4-fold higher odds of VF (adjusted OR 3.7, 95% CI 0.8–18.3) compared with those without, P?=?0.104. PDR prevalence increased to 18.2% (31/170) when LA-DRVs at ?2% were included. Participants with pretreatment LA-DRVs only had 1.6-fold higher odds of VF (adjusted OR 1.6, 95% CI 0.6–4.3) compared with those without, P?=?0.398.

Conclusions

Pretreatment DRMs and LA-DRVs increased the odds of developing VF on NNRTI-based ART, although without statistical significance. NGS increased detection of DRMs but provided no additional benefit in identifying participants at risk of VF at lower thresholds. More studies assessing mutation thresholds predictive of VF are required to inform use of NGS in treatment decisions.

Download: Full text paper

Citation: Chimukangara B, Giandhari J, Lessells J, Yende-Zuma N, Sartorius B, Samuel R, Khanyile KS, Stray-Pedersen B, Moodley P, Metzner KJ, Padayatchi N, Naidoo K, de Oliveira T. Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals Journal of Antimicrobial Chemotherapy,75, 11:3319–3326, https://doi.org/10.1093/jac/dkaa343 (2020).

05

Get in Touch
and Visit Us

Director

Prof. Tulio de Oliveira

School of Data Science & Computational Thinking, Stellenbosch University

KZN Research Innovarion and Sequencing Platform (KRISP) at UKZN.

Laboratories

CERI-Tyger – Tygerberg Medical School, Stellenbosch University

CERI-KRISP – Nelson R Mandela School of Medicine, UKZN.

Mon-Fri: 9:00 – 17:00
Sat-Sun: Closed

newsletter

Get our newsletter once a month to get in contact with us

© 2021 Centre for Epidemic Response and Innovation (CERI).

An institute of the Chan Soon Shiong Family Foundation, University of Stellenbosch and the University of KwaZulu-Natal. All rights reserved.